# Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

> **NCT01990196** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** degarelix
- **DRUG:** enzalutamide
- **DRUG:** trametinib
- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT01990196
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-09-23
- **Primary completion:** 2024-09-23
- **Final completion:** 2026-09-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01990196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01990196, "Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01990196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*